Delving into the Latest Updates on Yang Yin Fu Zheng Jie Du Prescription with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms-

Target-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication-

Inactive Indication

Hepatitis B Virus-Related Hepatocellular Carcinoma

Originator Organization

Beijing Ditan Hospital

Active Organization-

Inactive Organization

Beijing Ditan Hospital

Drug Highest PhasePendingEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

Clinical research of Yang Yin Fu Zheng Jie Du therapy in HBV associated Hepatocellular Carcinoma based on the platelet count/splenic length-diameter ratio.The purpose of this study is to establish the efficacy evaluation system combined with platelet/splenic length-diameter ratio, and to clarify the effect of this method on relieving hepatitis B cirrhosis and delaying the progression of Hepatocellular Carcinoma.

Start Date01 Oct 2020

Sponsor / Collaborator

Beijing Ditan Hospital

NCT05088733 / Unknown statusEarly Phase 1IIT

Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia

Clinical research of Yang Yin Fu Zheng Jie Du therapy in HBV related hepatocellular carcinoma induced anemia. The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy for patients belong to HBV-HCC induced anemia.

Start Date01 Jul 2020

Sponsor / Collaborator

Beijing Ditan Hospital

NCT04264962 / CompletedEarly Phase 1IIT

Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter

Clinical research of Yang Yin Fu Zheng Jie Du therapy in recurrence of Hepatocellular Carcinoma less than 3 cm in diameter.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy in 1 year recurrence for patients belong to Hepatocellular Carcinoma less than 3 cm in diameter.

Start Date01 Jan 2017

Sponsor / Collaborator

Beijing Ditan Hospital

[+1]

100 Clinical Results associated with Yang Yin Fu Zheng Jie Du Prescription

Login to view more data

100 Translational Medicine associated with Yang Yin Fu Zheng Jie Du Prescription

Login to view more data

100 Patents (Medical) associated with Yang Yin Fu Zheng Jie Du Prescription

Login to view more data

3

Literatures (Medical) associated with Yang Yin Fu Zheng Jie Du Prescription

01 Jun 1990·Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine

[Effects of fu-zheng jie-du decoction and cyclophosphamidum on the production of tumor necrosis factor in mice].

Article

Author: Wei, Y

Fu-Zheng Jie-Du decoction (FZJD) was an adjuvant drug of anti-tumor. In the present paper, the authors studied the effects of FZJD and cyclophosphamidum (CTX) on tumor necrosis factor (TNF) production of peritoneal macrophages (PM) of normal and EMT6 solid tumor-bearing mice. The results showed that in vitro, lipopolysaccharide (LPS) could induce TNF production of PM of normal mice; in contrast; FZJD and CTX were unable to induce TNF and inhibited the LPS effect. In vivo, CTX could not influence the TNF production of PM of tumor-bearing mice but FZJD could enhance the TNF production of PM of tumor-bearing mice treated with CTX.

Frontiers in Pharmacology

Effect of Fu Zheng Jie Du Formula on outcomes in patients with severe pneumonia receiving prone ventilation: a retrospective cohort study

Article

Author: Cai, Xingui ; Lai, Ting ; Chen, Bojun ; Chen, Li ; Zhao, Shuai ; Cai, Hairong ; Zhuang, Jieqin ; Li, Zhishang ; Luo, Sicong ; Ye, Ye ; Zhang, Weizhang

BackgroundThe effect of combining prone ventilation with traditional Chinese medicine on severe pneumonia remains unclear.ObjectiveTo evaluate the effect of Fu Zheng Jie Du Formula (FZJDF) combined with prone ventilation on clinical outcomes in patients with severe pneumonia.MethodsThis single-center retrospective cohort study included 188 severe pneumonia patients admitted to the ICU from January 2022 to December 2023. Patients were divided into an FZJD group (receiving FZJDF for 7 days plus prone ventilation) and a non-FZJD group (prone ventilation only). Propensity score matching (PSM) was performed to balance baseline characteristics. The primary outcome was the change in PaO2/FiO2 ratio after treatment. Secondary outcomes included 28-day mortality, duration of mechanical ventilation, length of ICU stay, PaCO2, lactic acid levels, APACHE II score, SOFA score, Chinese Medicine Score, inflammatory markers, and time to symptom resolution.ResultsAfter PSM, 32 patients were included in each group. Compared to the non-FZJD group, the FZJD group showed significantly higher PaO2/FiO2 ratios, lower PaCO2, and lower lactic acid levels after treatment (p < 0.05 for all). The FZJD group also had significantly lower APACHE II scores, SOFA scores, Chinese Medicine Scores, and levels of WBC, PCT, hs-CRP, and IL-6 (p < 0.05 for all). Time to symptom resolution, including duration of mechanical ventilation, length of ICU stay, time to fever resolution, time to cough resolution, and time to resolution of pulmonary rales, was significantly shorter in the FZJD group (p < 0.05 for all). There was no significant difference in 28-day mortality between the two groups.ConclusionFZJDF as an adjuvant therapy to prone ventilation can improve oxygenation and other clinical outcomes in severe pneumonia patients. Prospective studies are warranted to validate these findings.

Frontiers in Pharmacology

Effect of Fu Zheng Jie Du Formula on outcomes in patients with severe pneumonia receiving prone ventilation: a retrospective cohort study

Article

Author: Lai, Ting ; Zhuang, Jieqin ; Li, Zhishang ; Zhao, Shuai ; Zhang, Weizhang ; Ye, Ye ; Chen, Bojun ; Cai, Hairong ; Cai, Xingui ; Chen, Li ; Luo, Sicong

BackgroundThe effect of combining prone ventilation with traditional Chinese medicine on severe pneumonia remains unclear.ObjectiveTo evaluate the effect of Fu Zheng Jie Du Formula (FZJDF) combined with prone ventilation on clinical outcomes in patients with severe pneumonia.MethodsThis single-center retrospective cohort study included 188 severe pneumonia patients admitted to the ICU from January 2022 to December 2023. Patients were divided into an FZJD group (receiving FZJDF for 7 days plus prone ventilation) and a non-FZJD group (prone ventilation only). Propensity score matching (PSM) was performed to balance baseline characteristics. The primary outcome was the change in PaO2/FiO2 ratio after treatment. Secondary outcomes included 28-day mortality, duration of mechanical ventilation, length of ICU stay, PaCO2, lactic acid levels, APACHE II score, SOFA score, Chinese Medicine Score, inflammatory markers, and time to symptom resolution.ResultsAfter PSM, 32 patients were included in each group. Compared to the non-FZJD group, the FZJD group showed significantly higher PaO2/FiO2 ratios, lower PaCO2, and lower lactic acid levels after treatment (p < 0.05 for all). The FZJD group also had significantly lower APACHE II scores, SOFA scores, Chinese Medicine Scores, and levels of WBC, PCT, hs-CRP, and IL-6 (p < 0.05 for all). Time to symptom resolution, including duration of mechanical ventilation, length of ICU stay, time to fever resolution, time to cough resolution, and time to resolution of pulmonary rales, was significantly shorter in the FZJD group (p < 0.05 for all). There was no significant difference in 28-day mortality between the two groups.ConclusionFZJDF as an adjuvant therapy to prone ventilation can improve oxygenation and other clinical outcomes in severe pneumonia patients. Prospective studies are warranted to validate these findings.

100 Deals associated with Yang Yin Fu Zheng Jie Du Prescription

Login to view more data